Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Fluoroquinolones Need REMS With Communication Plan, AdCom Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Overwhelming votes against existing labels for the antibiotics likely means sponsors and FDA have some safety planning to do.


Related Content

Fluoroquinolones Get New Safety Labeling, But Not A REMS
FDA Adverse Event Data Clouds Potential Fluoroquinolone Label Changes
Recent And Upcoming FDA Advisory Committee Meetings
Fluoroquinolones: Is Another FDA Safety Step Needed?
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk


Related Companies